India, March 20 -- Shares of Windtree Therapeutics, Inc. (WINT) surged over 80% on Thursday morning after the company announced License and Supply agreement to become sourcing partner for Evofem Biosciences, Inc. (EVFM) for one of Evofem's FDA-approved products, Phexxi.
WINT is currently trading at $3.0900, up $1.4000 or 82.8402%, on a huge volume of 81 million shares, above average volume of 355 thousand, on the Nasdaq. The stock opened its trading at $2.5559 after closing Wednesday at $1.6900. The stock has traded between $1.6200 and $737.5000 in the past 52-week period.
The product is a first-in-class hormone-free, on-demand prescription contraceptive vaginal gel that women control. Phexxi annual revenues have grown to more than $19 mi...